Israeli Healthcare and Life Sciences Legal Update | February 2021

IMCA’s Procedure 106 – Update

The Israeli Medical Cannabis Agency (“IMCA”), which has established in 2011 and was granted the authority to issue licenses for the use of cannabis for medical purposes, has issued, in March 2013, Procedure 106, titled “Licenses for the Use of Cannabis”. Procedure 106 regulates the means of issuing a permit for the use of medical cannabis. Procedure 106 lists all the indications approved by the Israeli Ministry of Health for medical cannabis use and is updated by IMCA from time to time.

IMCA updated Procedure 106 in January 2021 to include approval of a new indication for medical cannabis – for behavioral disorders associated with autism spectrum disorder. The updated Procedure 106 specifies the criteria by which medical cannabis can be prescribed to patients under this new indication (e.g. the patient must suffer from at least grade 5 behavioral disorders according to S-CGI), as well as the type of medical cannabis products approved for such indication (e.g. medical cannabis oil CBD C28/T1).


For additional information please contact your GKH attorney or one of the following Adv. Hili Cohen, partner and head of life sciences department (, Adv. Dr. Eyal Diskin, partner (, Adv. Tami Fishman, partner (, or Adv. Ofir Goldstein (

Gross Law Firm (GKH) is one of the leading law firms in Israel, with over 170 attorneys. GKH specializes, both in Israel and abroad, in various fields of law including Mergers and Acquisitions, Capital Markets, Technology, Healthcare and Life Science, Banking, Real Estate, Project Finance, Litigation, Antitrust, Energy and Infrastructure, Environmental Law, Intellectual Property, Labor Law and Tax. This alert is prepared as an informational service to clients and colleagues of Gross & Co. (GKH) and the information presented is not intended to provide legal opinions or advice. Readers should seek professional legal advice regarding the matters about which they are particularly concerned.